Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE

This study has been completed.

Sponsor:

Collaborator:

Merck

Information provided by (Responsible Party):

Jane Armitage, University of Oxford

ClinicalTrials.gov Identifier:

NCT00461630

First received: April 17, 2007

Last updated: November 19, 2012

Last verified: November 2012

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been completed.
Study Completion Date:	October 2012
Primary Completion Date:	October 2012 (Final data collection date for primary outcome measure)